Fink, Katharina
Karolinska Institutet
2 papers on CoChatORCID 0000-0002-0030-0236
Most cited papers
- Verified
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet
Multiple Sclerosis Research StudiesSphingolipid Metabolism and Signaling
Cited by 942
- Verified
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Luna, G., Alping, P., Burman, J., Fink, K., Fogdell-Hahn, A., Gunnarsson, M., Hillert, J., Langer-Gould, A., Lycke, J., Nilsson, P., et al. (2020) · JAMA Neurology
Multiple Sclerosis Research StudiesPharmacovigilance and Adverse Drug Reactions
Cited by 521
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free